Compare MHH & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | KPTI |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 94.6M |
| IPO Year | N/A | 2013 |
| Metric | MHH | KPTI |
|---|---|---|
| Price | $6.93 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 29.9K | ★ 117.3K |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,657,000.00 | $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | $4.52 | $3.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $6.20 | $3.51 |
| 52 Week High | $16.00 | $12.45 |
| Indicator | MHH | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 50.33 |
| Support Level | $7.34 | $5.30 |
| Resistance Level | $8.37 | $6.05 |
| Average True Range (ATR) | 0.57 | 0.44 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 7.93 | 37.50 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.